Targeting breast cancer with specialized nanoparticles
Macrophage-specific nanotherapy for breast cancer
This study is looking at a new way to help your body fight breast cancer by using tiny particles that deliver special treatments to immune cells, helping them better attack the cancer while aiming to reduce side effects from traditional therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Michigan State University NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-11063976 on NIH RePORTER |
What this research studies
This research focuses on enhancing the body's ability to fight breast cancer by using nanoparticles that deliver specific inhibitors to immune cells called macrophages. These nanoparticles aim to overcome the cancer's defense mechanisms that prevent immune cells from attacking tumor cells. By restoring the process of phagocytosis, where immune cells engulf and eliminate cancer cells, the research seeks to improve treatment outcomes while minimizing side effects typically associated with current therapies. The study will utilize animal models to test the effectiveness of these nanoparticles in delivering the inhibitors directly to the tumor-infiltrating macrophages.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with breast cancer who are seeking innovative treatment options.
Not a fit: Patients with non-breast cancer types or those who are not eligible for experimental therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective breast cancer treatments with fewer side effects.
How similar studies have performed: Previous research has shown promise in using nanoparticles for targeted drug delivery in cancer treatment, indicating potential success for this approach.
Where this research is happening
East Lansing, United States
- Michigan State University — East Lansing, United States (Active)
Researchers
- Principal investigator: Smith, Bryan Ronain — Michigan State University
- Study coordinator: Smith, Bryan Ronain
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.